First Trust Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

First Trust Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-57,258	Closed	-$6.14M	–	2477
2023 Q1	$6.14M	Sell	57,258 -59,276	-51%	-$6.82M	0.01%	1141
2022 Q4	$12.8M	Buy	116,534 +26,916	+30%	+$1.75M	0.02%	889
2022 Q3	$5.29M	Sell	89,618 -34,351	-28%	-$1.57M	0.01%	1164
2022 Q2	$3.5M	Buy	123,969 +93,952	+313%	+$2.72M	﹤0.01%	1454
2022 Q1	$1.13M	Buy	+30,017	New	+$1.19M	﹤0.01%	2006

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

First Trust Advisors's RXDX Position: Q2 2023 in Review

First Trust Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 57,258 shares — an estimated $6.14M sold.

First Trust Advisors first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $12.8M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

First Trust Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
First Trust Advisors sold 57,258 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $6.14M.
First Trust Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
First Trust Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $12.8M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on First Trust Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.